CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
GlyCanDrug is a research initiative focused on developing precision therapies targeting cancer-associated glycans. By training doctoral candidates in glycoscience, it aims to enhance cancer treatment options and contribute to innovative therapeutic solutions.
Glycoscience has gained such significant technological advances over the past decade, that it is now poised for giving an unprecedented contribution to high-demanding societal needs.
GlyCanDrug is a glycoscience-oriented DN that aims, for the first time, to take a step ahead in the design of precision therapeutics targeting key glycan motifs implicated in cancer.
These glycans are fingerprints of many cancers.
Thus, their targeting has the striking potential to overcome cancer heterogeneity that…
UNIVERSITA DEGLI STUDI DI FIRENZE
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
I3S - INSTITUTO DE INVESTIGACAO E INOVACAO EM SAUDE DA UNIVERSIDADE DO PORTO
Portugal, PORTO
Type: Research institute
Activity type: Research Organisations
SME: No
Spain, Zaragoza
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
TECHNICAL UNIVERSITY OF DENMARK DTU
Denmark, Kongens Lyngby
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Slovenia, Ljubljana
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
